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Edited by Christian GriesingerAbstract The a-conotoxin RgIA is a selective antagonist of the
a9a10 nicotinic acetylcholine receptor and has been shown to be
a potent analgesic and reduces nerve injury associated inﬂamma-
tion. RgIA was chemically synthesized and found to fold into two
disulﬁde isomers, globular and ribbon. The native globular iso-
mer inhibited ACh-evoked currents reversibly in oocytes express-
ing rat a9a10 nAChRs but the ribbon isomer was inactive. We
determined the three-dimensional structure of RgIA using
NMR methods to assist in elucidating the molecular role of
RgIA in analgesia and inﬂammation.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Conotoxins are disulﬁde rich peptides from the venom of
marine snails of the Conus genus [1]. They are potent and selec-
tive ligands for a range of ion channels and have considerable
therapeutic potential especially as analgesics [2,3]. The a-cono-
toxins (Fig. 1) speciﬁcally target muscle and neuronal nicotinic
acetylcholine receptors (nAChRs) with high potency and selec-
tivity [4]. They range in size from 12 to 19 amino acids, contain
two disulﬁde bonds in a I–III, II–IV topology and have a
three-dimensional structure dominated by an a-helix believed
to be the scaﬀold that presents the amino acid side chains in
the correct orientation for receptor binding [5].
a-Conotoxins, RgIA [6] and Vc1.1 [7] have potent analgesic
activity in rat models of neuropathic pain [8,9]. Both of these
conotoxins are speciﬁc antagonists of the a9a10 subtype of
the nAChR and it was originally proposed that blocking this
subtype produced analgesia [9]. However, it has been recently
proposed that the a9a10 nAChR is not the analgesic target
for these conotoxins as several modiﬁed analogues of Vc1.1
are still equipotent at the a9a10 nAChR but have no analgesic
activity [10]. The a-conotoxins can be further classiﬁed based
on the spacing between cysteines II and III and cysteines III
and IV. Interestingly, Vc1.1 and RgIA belong to diﬀerent clas-
ses of a-conotoxins, 4/7 and 4/3, respectively, yet they target the
same receptor subtype. Determination of the 3D structure of*Corresponding author. Fax: +61 7 3346 2029.
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doi:10.1016/j.febslet.2008.01.027RgIA may yield insights into the factors that make RgIA spe-
ciﬁc for the a9a10 nAChR subtype. Because of their small size
and well-deﬁned structures, conotoxins are ideally suited to
structural determination using nuclear magnetic resonance [11].
This study describes the synthesis, oxidative folding and
structural elucidation by NMR of the a-conotoxin RgIA. De-
tailed structural analysis of RgIA will provide a basis for
establishing structure/function relationships and may facilitate
structure-based design studies to produce more potent and
selective analgesic molecules.2. Materials and methods
2.1. Peptide synthesis
RgIA was assembled by solid-phase peptide synthesis using the
in situ neutralization/HBTU protocol for Boc chemistry [12]. The crude
peptide was puriﬁed by RP-HPLC and characterized by RP-HPLC and
ES-MS. The peptide was oxidized in 0.1 MNH4HCO3 (pH 8.2) at room
temperature. An alternative oxidation buﬀer of 25% propan-2-ol in
0.1 MNH4HCO3 (pH 8.2) was also used that favoured the more hydro-
phobic globular RgIA disulﬁde isomer. The oxidized peptide was puri-
ﬁed by RP-HPLC. The disulﬁde connectivity of the two isomers was
conﬁrmed using a partial reduction/alkylation strategy with subsequent
MS/MS sequencing as described previously [13].2.2. Electrophysiology
RNA preparation, oocyte preparation and expression of nAChR
subunits in Xenopus oocytes were performed as described previously
[13]. Plasmids with cDNA encoding the rat a9 and a10 nAChR sub-
units were kindly provided by Dr. A.B. Elgoyhen (Universidad de Bue-
nos Aires, Argentina). Oocytes were injected with 5 ng of cRNA and
kept at 18 C in ND96 buﬀer (96 mM NaCl, 2 mM KCl, 1.8 mM
CaCl2, 1 mM MgCl2 and 5 mM HEPES at pH 7.4) supplemented with
50 mg/l gentamycin and 5 mM pyruvic acid 2–5 days before recording.
All recordings were conducted at 20–23 C using a bath solution of
ND96 as described above. During recordings, the oocytes were super-
fused continuously at a rate of 1.5 ml/min, with 300 s incubation times
for the conotoxin. Acetylcholine (ACh; 100 lM) was applied for 2 s at
5 ml/min, with 300 s washout periods between applications. RgIA was
co-applied with the agonist. Cells were voltage clamped at a holding
potential of 80 mV. Data were sampled at 500 Hz and ﬁltered at
200 Hz. Peak current amplitude was measured before and following
incubation of the peptide. All data were pooled (n = 3–9 for each data
point) and represent as arithmetic means ± S.E.M., Hill equation was
used to ﬁt concentration–response curves using SigmaPlot 8.0 (Jandel
Corporation, San Rafael, CA).2.3. NMR spectroscopy and structure calculations
NMR data for RgIA were recorded on a sample in 90% H2O/10%
D2O at pH 3.5 using a Bruker ARX 600 MHz spectrometer. 2D
NMR experiments included DQF-COSY, E-COSY, TOCSY and
NOESY, with all spectra recorded at 280–290 K. A series of 1D and
TOCSY spectra acquired immediately following the dissolution ofblished by Elsevier B.V. All rights reserved.
Table 1
NMR and reﬁnement statistics for RgIA
NMR distance and dihedral constraints
Total NOE 55
Sequential (|i  j| = 1) 30
Medium-range (|i  j| < 4) 18
Long-range (|i  j > 5) 4
/ Restraints 6
Structure statistics
Violations (mean and S.D.)
Distance constraints (A˚) 0.04 ± 0.007
Dihedral angle constraints () 0.28 ± 0.32
Maximum dihedral angle violation () 3
Maximum distance constraint violation (A˚) 0.3
Deviations from idealized geometry
Fig. 1. The a-conotoxins. (A) Selected a-conotoxin sequences showing the cystine frameworks of the globular and ribbon disulﬁde isomers and the
two loops used to deﬁne the subclasses of a-conotoxins. The asterisk indicates an amidated C-terminus. (B) Conserved structural scaﬀold of the a-
conotoxins, consisting of two disulﬁde bonds in a I–III, II–IV arrangement and a central helical region.
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exchanging NH protons. Peak intensities from a NOESY spectrum
with a mixing time of 300 ms at 290 K were used to determine distance
restraints. Backbone dihedral restraints were determined from 3JHN–Ha
coupling constants and / angles were restrained to 60 ± 30 for
3JHN–Ha < 5.8 Hz. Intra-residue NOE and
3JHa–Hb coupling patterns
were used in assigning v1 angle restraints of some side chains. Two re-
straints were included for a hydrogen bond identiﬁed from D2O ex-
change data and preliminary structures.
Initial structures were generated using Cyana software [14] and the
ﬁnal structure calculations were performed using a simulated annealing
protocol with CNS [15] as previously described [13]. Fifty structures
were calculated and the 20 with the lowest overall energies were re-
tained for analysis (see Table 1). Structures were visualized using
MOLMOL [16] and analysed with PROMOTIF [17] and PRO-
CHECK_NMR [18].Bond lengths (A˚) 0.004 ± 0.0002
Bond angles () 0.55 ± 0.06
Impropers () 0.44 ± 0.09
Average pairwise r.m.s.d.a (A˚)
Backbone atoms (residues 2–11) 0.46 ± 0.15
Heavy atoms (residues 2–11) 1.73 ± 0.35
Ramachandran statistics
Percentage of residues in most favoured
region
77
Percentage of residues in additionally allowed
region
23
aPairwise r.m.s.d. was calculated among 20 reﬁned structures.3. Results
The conotoxin RgIA was successfully assembled by solid
phase peptide synthesis and the disulﬁde bonds were formed
using a direct oxidative folding approach in aqueous buﬀer at
basic pH. Using NH4HCO3 buﬀer alone resulted in the forma-
tion of two disulﬁde isomers in an approximately 1:1 ratio as
shown in Fig. 2. The disulﬁde connectivity of these two isomers
was determined to be the native globular isomer (Cys2-Cys8,
Cys3-12) and the non-native ribbon isomer (Cys2-Cys12,
Cys3-Cys8). Addition of 25% propan-2-ol to the folding buﬀer
resulted in a greater proportion of the globular isomer being
formed as this isomer is more hydrophobic, as reﬂected in its
later elution time on RP-HPLC (Fig. 2B). Addition of a hydro-
phobic co-solvent is often used to promote formation of the na-
tive disulﬁde isomer when folding conotoxins using a direct
oxidation approach. For example, formation of the globular
isomer of ImI, which is a member of the same 4/3 sub-class
of a-conotoxins as RgIA, is promoted by the addition of meth-
anol, ethanol or propan-2-ol to the folding buﬀer [19].
NMR data were recorded at 280 K for both isomers; the
spectra were assigned and chemical shift analysis indicated that
the globular isomer was structurally more similar to the related
conotoxin ImI than the ribbon isomer (Fig. 3A). The globular
isomer also showed a series of negative secondary shift values
for residues 6–9, which is indicative of helical character and
consistent with the conserved a-conotoxin framework [4]. In
parallel, the eﬀect of each isomer on ACh-evoked currents in
Xenopus oocytes expressing the rat a9a10 nAChR subtypewas investigated (Fig. 2). The globular isomer inhibited the
ACh (100 lM)-evoked current reversibly with an IC50 of
22 nM (Hill coeﬃcient = 0.9) but the ribbon isomer exhibited
no inhibition at concentrations up to 1 lM. On the basis of
the preliminary NMR and biological activity data, a three-
dimensional structure of the native/globular and active isomer
of RgIA was determined. The ribbon isomer was not structur-
ally characterized as it was inactive at the a9a10 nAChR.
The NMR spectra recorded on RgIA showed single spin sys-
tems for each residue of the peptide. Several residues including
Asp5, Tyr10 and Cys12 have broadened resonances, which indi-
cates that there may be some localized conformational ex-
change. Despite this broadening, there were suﬃcient NOEs
to calculate a 3D structure using a simulated annealing proto-
col in CNS. A set of 50 structures was calculated with 55 dis-
tance restraints consisting of three intra-residue, 30 sequential,
18 medium range and four long range restraints. Six / angle
restraints were included and two v1 angle restraints. Two re-
straints for one hydrogen bond between Cys8 HN and Asp5
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Fig. 2. Oxidative folding and biological activity of RgIA. (A) RP-HPLC oxidation proﬁle of RgIA using 0.1 M NH4HCO3 (pH 8.2). (B) RP-HPLC
oxidation proﬁle of RgIA using 25% propan-2-ol in 0.1 M NH4HCO3 (pH 8.2). (C) Representative superimposed current traces evoked by 100 lM
ACh without (control) and with 1 lM RgIA-ribbon and 10 nM RgIA-globular. (D) Concentration–response curves obtained for the inhibition of
ACh-evoked peak current amplitudes by RgIA-globular (open circles) and RgIA-ribbon (open triangles). All data were pooled (n = 3–9 for each data
point) and represent as arithmetic means ± S.E.M.
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Fig. 3. NMR structure of RgIA. (A) Secondary shift analysis of the two isomers of RgIA compared to ImI [20]. Secondary shifts of the globular
RgIA isomer (ﬁlled squares) are more comparable to those of ImI (open triangles) than those of the ribbon isomer (open squares). (B) NMR
structure ensemble of RgIA. The peptide backbone is shown in blue and disulﬁde bonds are shown in yellow. (C) Mean 3D structure of RgIA
showing the 3–10 helices.
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600 R.J. Clark et al. / FEBS Letters 582 (2008) 597–602O were included based on the analysis of slow exchange data
and preliminary structures. The 20 lowest energy structures
were chosen to represent the structure of RgIA and this ensem-
ble is shown in Fig. 3B. A relatively well-deﬁned structure was
obtained, as shown by the RMSD over residues 2–11 of
0.46 ± 0.14 A˚ for the backbone atoms.
Analysis of the structures with PROMOTIF [17] identiﬁed a
type I b-turn between residues 2 and 5, a 310 helix between res-
idues 5 and 9, and a type VIII b-turn between residues 9 and
12. The disulﬁde bond between Cys2 and Cys8 is characterized
as a right-handed hook in approximately half the structures
and the disulﬁde bond between residues Cys3 and Cys12 does
not have a preferred conformation. The mean structure of
the ensemble is shown in Fig. 3C and the structural data have
been deposited in the Biological Magnetic Resonance Data
Bank (http://www.bmrb.wisc.edu/).4. Discussion
RgIA is classiﬁed as a 4/3 a-conotoxin and the only other
member of this sub-family for which a 3D structure has been
determined is ImI [20–22]. The three published ImI structures
show a very similar structure for loop 1 but the structures di-
verge in loop 2. There are also two X-ray crystal structures ofR9
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Fig. 4. Structural comparison of RgIA with ImI and Vc1.1 (A) Backbone sup
PDB ID 2C9T) over loop 1. Sidechains of the loop 2 residues are shown with
the polar hydroxyl group of tyrosine in grey. (B) Backbone superposition of
(residues 2–8). (C) Molecular surfaces of RgIA (top) and ImI (bottom). Positi
polar residues, grey; and glycine cyan.ImI bound to the AChBP from Aplysia, which is a soluble
homolog of the ligand binding domain of the nAChR
[23,24]. Unlike RgIA, ImI is a selective inhibitor of the human
a3b2 and a7 nAChR subtypes (IC50 = 41 and 595 nM, respec-
tively) and is less potent at the a9a10 subtype (1.9 lM) [6,25].
Both ImI and RgIA share an identical loop 1 sequence but
have diﬀerent loop 2 sequences and it is proposed that this var-
iation in the loop 2 sequences results in the diﬀerences in
nAChR subtype selectivity of these two conotoxins [26].
Fig. 4 shows a comparison of the structure of RgIA with the
crystal structure of ImI bound to the receptor where the resi-
dues from loop 1 have been overlaid. Loop 2 of RgIA matches
quite closely to that of the bound ImI structure and suggests
that similar binding modes are likely and that the diﬀerences
in selectivity of the two conotoxins are due to the diﬀerences
in the side chains of the three loop 2 residues. RgIA contains
two arginines in loop 2 and one C-terminal arginine. This is re-
ﬂected in the surface of the molecule (Fig. 4C), which is dom-
inated by these positively charged residues and is in contrast to
ImI which has a large hydrophobic patch comprizing Pro6
(from loop 1), Ala9 and Trp10 (from loop 2). Of the three loop
2 residues, the biggest diﬀerence between RgIA and ImI is at
position 9, which is a large positively charged residue (Arg)
in RgIA but a small hydrophobic residue (Ala) in ImI. In
the crystal structure of ImI bound to the AChBP, Ala9 makesrg9 Trp10
Arg11
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Trp10
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180o
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erposition of RgIA (orange) and the AChBP bound ImI (purple, from
positively charged residues in blue, hydrophobic residues in green and
RgIA (orange) and Vc1.1 (blue, PDB ID 2h8s) overlayed over loop 1
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nAChR subtypes have a hydrophobic isoleucine or leucine,
respectively, at position 116 but in the a9 and a10 nAChR sub-
units this hydrophobic residue is replaced by a negatively
charged aspartic acid. It has been proposed that Arg9 in RgIA
could form a salt bridge with the aspartic acid at position 116,
which results in RgIA being selective for the a9a10 nAChR
subtype [26]. The structure of RgIA is consistent with this pro-
posal as the side chains of the residues at position 9 in both
RgIA and bound ImI have a similar orientation (Fig. 4A)
and therefore Arg9 in RgIA could potentially interact with
Asp116 of the receptor.
The a-conotoxin Vc1.1, like RgIA, is selective for the a9a10
nAChR subtype and its loop 1 sequence is identical to that of
RgIA. However, Vc1.1 is a member of the 4/7 subclass of
a-conotoxins and has seven residues in loop 2 in contrast to
RgIA, which has only three residues (Fig. 4B). Of the ﬁrst
three loop 2 residues of Vc1.1, only the tyrosine at position
10 is the same as RgIA. Importantly, the arginine at position
9 in RgIA that is believed to have a major role in the a9a10
selectivity of RgIA, by the formation of a salt bridge with
the receptor, is an asparagine in Vc1.1 and therefore Vc1.1
cannot form this salt bridge. Vc1.1 clearly is capable of making
receptor contacts that RgIA cannot make, simply due to its
larger 2nd loop and these additional contacts are likely to re-
sult in the a9a10 selectivity of Vc1.1.
In conclusion, we have described the synthesis, folding and
three-dimensional structure of RgIA, a selective antagonist
of the a9a10 nAChR. This subtype has been proposed to play
a role in the response to inﬂammation caused by nerve injury
[9] and selective ligands may be valuable tools for elucidation
of this pathway. Both RgIA and Vc1.1 have also been shown
to be potent analgesics in rat models of neuropathic pain
although the precise molecular target remains unknown [8–
10]. These structural data on RgIA will facilitate further struc-
ture/function studies to understand the molecular mechanism
of analgesia of these molecules via a range of approaches
including peptide and receptor mutagenesis, molecular model-
ling studies and peptide engineering [27,28]. Recent studies on
the a-conotoxin MII and the l-conotoxin SIIIA, for example,
have shown that structure guided engineering can be used to
produce stabilized conotoxins via cyclization [27] or backbone
prosthesis [28] that are potential drug leads.
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